… of acquired resistance to EGFR- or ALK-directed TKI therapy in NSCLC be broadly subtyped
into 1) central nervous system (CNS) sanctuary PD, 2) oligo-PD and 3) systemic PD, for …

… and erlotinib acquired resistance in an erlotinib sensitive EGFR-mutant lung cancer cell line.
… of EMT in the development of treatments against acquired resistance to gefitinib or erlotinib. …

… of patients whose tumors develop acquired resistance to EGFR TKIs. Our standard approach
to treatment of EGFR-mutant lung cancer with acquired resistance to EGFR TKI therapy is …

… in vivo in EGFR-mutant lung cancer models of acquired resistance to erlotinib in the absence
of … in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKI. …

… –small-cell lung cancer, 10 with colorectal cancer, and 1 with … This study focused on acquired
resistance mechanisms in … Mechanisms of acquired resistance to sotorasib are currently …

… of different resistance mechanisms has not been well documented in the literature. The
aim of our study was to elucidate the mechanisms of acquired resistance to osimertinib and to …

Introduction With expanding indications for programmed death 1 (PD-1) axis inhibitors in
non–small cell lung cancer (NSCLC), acquired resistance (AR) to these therapies is …

… Mechanisms of resistance to EGFR TKIs … or an acquired resistance to TKIs: patients with
primary resistance are initially refractory to treatment, whereas acquired resistance may occur in …

… has resulted in acquired resistance now loosely referring to EGFR-mutant lung cancers with
… Acquired resistance to EGFR kinase inhibitors is believed to be initiated by the emergence …

… -TKIs and their underlying resistance mechanisms in both the … -naïve and -resistant patients
with lung cancer harboring the … In conclusion, the mechanisms of acquired resistance to ALK …